Kyverna Therapeutics

top of page

Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026

Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced...

Company News

Aug 13

Kyverna's CEO on B-cell depletion and CD19 CAR-T for autoimmune conditions

Peter Maag describes how Kyverna has been focused on this area for five years.

Company News

Mar 27, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026

Kyverna's CEO on B-cell depletion and CD19 CAR-T for autoimmune conditions

Follow BiotechTV

Sponsors

Sponsor Spotlight